Selective Orexin 2 Receptor Agonist Receives Breakthrough Therapy Designation for Narcolepsy Type 1

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton (Alkermes, Dublin, Ireland) for the treatment of narcolepsy type 1 (NT1), based on early clinical evidence demonstrating improvement in wakefulness outcomes. Breakthrough Therapy designation is intended to expedite development and regulatory review of therapies for serious conditions when preliminary data suggest substantial improvement over available treatments.

The designation was supported by clinical data including results from Vibrance-1 (NCT06358950), a randomized phase 2 clinical trial that included 92 adults with NT1. In Vibrance-1, treatment with once-daily oral alixorexton was evaluated across multiple dose levels compared with placebo. The primary efficacy end point was change from baseline in wakefulness as measured by the Maintenance of Wakefulness Test (MWT). Alixorexton is a selective orexin 2 receptor (OX2R) agonist and is being developed for NT1, narcolepsy type 2, and idiopathic hypersomnia. According to a statement from the company, Alkermes plans to initiate a global phase 3 program in narcolepsy in the first quarter of 2026.

Key findings reported from the Vibrance-1 study include the following:

• Alixorexton met the primary end point across all doses tested, demonstrating statistically significant and dose-dependent improvements in MWT performance compared with placebo.
• Improvements in wakefulness were described as clinically meaningful across the evaluated dose range.
• Alixorexton was generally well tolerated, with no new safety concerns reported across doses tested.

Source: Alkermes plc. Alixorexton granted breakthrough therapy designation by U.S. FDA for the treatment of narcolepsy type 1. Alkermes. Published January 6, 2026. Accessed January 9, 2026. https://investor.alkermes.com/news-releases/news-release-details/alixorexton-granted-breakthrough-therapy-designation-us-fda